News Release

Policy implications of orphan drug designation for remdesivir to treat COVID-19

Peer-Reviewed Publication

JAMA Network

What The Study Did: This Viewpoint highlights loopholes in U.S. orphan drug policy as exemplified by the use of remdesivir to treat COVID-19.

Authors: Kao-Ping Chua, M.D., Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2020.2759)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory: The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2020.2759?guestAccessKey=17d5c228-3e67-46bb-8c1a-212515e164a3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081720


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.